Back to search
Leukocyte Adhesion Deficiency, Type II
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Leukocyte Adhesion Deficiency, Type II trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Leukocyte Adhesion Deficiency, Type II trials you may qualify forThe primary objective of this extension study is to assess the long-term safety and efficacy of AVTX-803 in subjects with LAD II (SLC35C1-CDG).
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Ty…
This is a data collection study that will examine the general diagnostic and treatment data associated with the reduced-intensity chemotherapy-based regimen pai…
The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double…
This Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) is a continuation of a Phase 1/2 clinical study to evaluate the safe…
The primary purpose of the Phase I portion of the study is to assess the therapeutic safety and preliminary efficacy of a hematopoietic cell-based gene therapy…
Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II